Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report
The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5–10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treat...
Main Authors: | Maria Pokorska-Śpiewak, Anna Dobrzeniecka, Agnieszka Ogrodnik |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Infectious Disease Reports |
Subjects: | |
Online Access: | https://www.mdpi.com/2036-7449/14/4/61 |
Similar Items
-
The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C
by: Maria Pokorska-Śpiewak, et al.
Published: (2022-02-01) -
Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
by: Heidar Sharafi, et al.
Published: (2020-01-01) -
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
by: Ching-Chu Lo, et al.
Published: (2022-08-01) -
Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
by: Maria Pokorska-Śpiewak, et al.
Published: (2021-09-01) -
Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
by: Umer Ansari, BS, et al.
Published: (2017-01-01)